Retrophin to Report First Quarter 2014 Financial Results
Business Wire - Mon May 12, 1:45PM CDT
Retrophin, Inc. (NASDAQ:RTRX) announced today that it will report its first quarter 2014 financial results on Wednesday, May 14, 2014. The press release will be followed by a conference call and webcast at 8:30 a.m. ET.
Retrophin Initiates Global Access for RE-024 in Pantothenate Kinase-Associated Neurodegeneration (PKAN)
Business Wire - Mon May 12, 7:01AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced that it has made RE-024 available to physicians who are treating critically ill patients with pantothenate kinase-associated neurodegeneration (PKAN) worldwide under local "compassionate use" regulations. RE-024 is a replacement therapy for phosphopantothenate, the reaction product and substrate that is missing in patients with PKAN.
Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma
PR Newswire - Tue May 06, 11:37AM CDT
The U.S. markets on Monday, May 5, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the session 0.19% higher at 1,884.66. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, with the index advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Retrophin Inc. (NASDAQ: RTRX), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Gilead Sciences Inc. (NASDAQ: GILD) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on RTRX, MACK, GILD and RNN can be downloaded upon signing up at:
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate Updates - Analyst Notes on Insmed, Akebia, Retrophin, Agios and Spectranetics
PR Newswire - Wed Apr 23, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Akebia Therapeutics, Inc. (NASDAQ: AKBA), Retrophin, Inc. (NASDAQ: RTRX), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and The Spectranetics Corporation (NASDAQ: SPNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1455-100free.
Should You Get Rid of Retrophin (RTRX) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:41AM CDT
Retrophin (RTRX) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter as well as the current year.
Strength Seen in Retrophin, Inc. (RTRX) as Stock Shoots up 18% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 7:44AM CDT
Retrophin, Inc. was a big mover last session, as the company saw its shares surge ahead 18% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Retrophin Updates Financial Guidance for 2014 and 2015 and Provides Corporate Update
Business Wire - Mon Apr 14, 6:00AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced it is updating its revenue outlook for 2014 and 2015.
FDA Recommendations, Study Publications, Recognitions, Agreements, and Acquisitions - Analyst Notes on MannKind, Acceleron, Steris, Retrophin, and NxStage Medical
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ: XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX), and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
3 Biotech Stocks Rising on Unusual Volume
at The Street - Tue Apr 01, 5:00AM CDT
Keep these biotech stocks on your radar.
Retrophin Reports Full-Year 2013 Financial Results
Business Wire - Thu Mar 27, 8:11AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today reported its financial results for the year ended December 31, 2013.
The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs
Retrophin Completes Acquisition of Manchester Pharmaceuticals
Business Wire - Thu Mar 27, 7:01AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5 million, including an upfront payment of $29.5 million, plus other payments based on product sales.
Retrophin (RTRX) Catches Eye: Stock Moves 7.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 8:54AM CDT
Retrophin was a big mover last session, with shares rising nearly 8% on the day.